404 related articles for article (PubMed ID: 26290278)
1. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
Hao Y; Lin PL; Xie J; Li N; Koo V; Ohashi E; Wu EQ; Rogerio J
J Comp Eff Res; 2015 Aug; 4(4):315-26. PubMed ID: 26274793
[TBL] [Abstract][Full Text] [Related]
4. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites.
Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
Clin Ther; 2016 Apr; 38(4):905-17. PubMed ID: 26947172
[TBL] [Abstract][Full Text] [Related]
6. Everolimus Plus Letrozole for Treatment of Patients With HR
Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
[TBL] [Abstract][Full Text] [Related]
7. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
8. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
Li N; Hao Y; Xie J; Lin PL; Zhou Z; Zhong Y; Signorovitch JE; Wu EQ
Curr Med Res Opin; 2015 Aug; 31(8):1573-82. PubMed ID: 26074049
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
11. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
[TBL] [Abstract][Full Text] [Related]
12. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
Eur J Cancer; 2021 Feb; 144():341-350. PubMed ID: 33388491
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
14. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.
Lin PL; Hao Y; Xie J; Li N; Zhong Y; Zhou Z; Signorovitch JE; Wu EQ
Cancer Med; 2016 Feb; 5(2):209-20. PubMed ID: 26686532
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Campone M; Beck JT; Gnant M; Neven P; Pritchard KI; Bachelot T; Provencher L; Rugo HS; Piccart M; Hortobagyi GN; Nunzi M; Heng DY; Baselga J; Komorowski A; Noguchi S; Horiguchi J; Bennett L; Ziemiecki R; Zhang J; Cahana A; Taran T; Sahmoud T; Burris HA
Curr Med Res Opin; 2013 Nov; 29(11):1463-73. PubMed ID: 23962028
[TBL] [Abstract][Full Text] [Related]
20. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
